Blarcamesine Demonstrates Promising Outcomes in Alzheimer’s Treatment Trial
Anavex Life Sciences has announced promising findings from their Phase 2b/3 trial of
blarcamesine, a novel therapeutic candidate for early Alzheimer’s disease (AD).
The investigational drug, also known as ANAVEX2-73, by Anavex,
showed significant efficacy in reducing amyloid-ß biomarkers and slowing cognitive decline in patients.
The multicenter, randomized, double-blind, placebo-controlled study involved 508 participants
from various medical research centers across five countries. Participants were
assigned to receive either blarcamesine or a placebo daily for 48 weeks. Key
endpoints included the Alzheimer’s Disease Assessment Scale-Cognitive
(ADAS-Cog) and the Alzheimer’s Disease Cooperative Study-Activities of Daily
Living (ADCS-ADL).
According to Dr. Marwan Noel Sabbagh, professor of neurology and chairman of the Scientific
Advisory Board, the data from this trial offer hope for new treatment avenues
that go beyond traditional amyloid-targeting therapies. “The advantage of
blarcamesine is that it is a small oral molecule that exerts clinical benefits
on cognition and neurodegeneration,” Sabbagh noted.
According to Anavex Life Sciences, in terms of efficacy, blarcamesine-treated patients
exhibited a statistically significant increase in the plasma Aβ42/40 ratio (P =
.048), indicating its potent anti-amyloid effect. MRI scans also revealed a
significant reduction in brain volume loss (P = .0005), further substantiating
the drug’s neuroprotective properties.
Safety was also a focus of the study. Although dizziness was a common side effect, it was
generally mild to moderate and transient in nature. This adverse effect was
reported in 35.8% of participants during the titration phase and 25.2% during maintenance.
Christopher U. Missling, PhD, president and CEO of Anavex
Life Sciences, expressed gratitude for the collaborative efforts involved in this
groundbreaking study. “We look forward to advancing blarcamesine as a
potential new, convenient, orally available treatment option for Alzheimer’s disease,” Missling said.
These findings mark a significant step forward for Anavex and its commitment to addressing the
complexities of Alzheimer’s disease. With further research and development,
blarcamesine could potentially offer a new ray of hope for millions affected by
this debilitating condition. Refer to this article, for related information.
More about Anavex on https://www.instagram.com/anavexlifesci/
